Group 1 - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources have issued a plan to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, aiming to establish a convenient and efficient rural road network [1] - The plan includes implementing 300,000 kilometers of repair and maintenance projects, maintaining a good road condition rate of over 70%, and carrying out safety protection projects on 150,000 kilometers of roads [1] - The initiative aims to enhance rural transportation services and support the vision of a well-structured, high-quality rural transportation system by 2035 [1] Group 2 - U.S. stock markets saw an overall increase, with the Dow Jones rising by 81.38 points (0.19%) and the Nasdaq increasing by 252.87 points (1.21%) [2] - Notable stock movements included Apple rising by 5% due to anticipated investments in U.S. manufacturing, and McDonald's gaining over 3% following better-than-expected earnings [2] - Many popular Chinese concept stocks also saw gains, with Alibaba up over 3% and NIO increasing by over 2% [2] Group 3 - The State Grid reported a record high electricity load for three consecutive days, reaching a maximum load of 1.233 billion kilowatts, an increase of 53 million kilowatts compared to last year's peak [3] - The electricity load is expected to remain above 1.2 billion kilowatts, with a potential decrease anticipated due to upcoming rainfall and cooler temperatures [3] Group 4 - The Hong Kong Monetary Authority intervened in the currency market, buying HKD 8.439 billion after the Hong Kong dollar hit the weak end of its trading band [4] - This action is part of the linked exchange rate system, where the HKMA sells USD and buys HKD to stabilize the currency [4] Group 5 - The China Photovoltaic Industry Association is soliciting opinions on the draft amendment to the Price Law, focusing on price behavior norms and regulatory mechanisms [5] - This initiative aims to reflect the demands of the photovoltaic industry and gather feedback for potential modifications [5] Group 6 - Guangnan Group's subsidiary successfully acquired land use rights in Foshan for RMB 56.16 million, expanding its meat industry chain [6] Group 7 - Caocao Travel is exploring the tokenization of real-world assets and stablecoin payments through a strategic partnership with a licensed financial institution in Hong Kong [7][8] Group 8 - Lianzhong is integrating AI technology into traditional board games, collaborating with tech companies to enhance gaming experiences [9] Group 9 - China National Pharmaceutical Group's self-developed drug TQ05105 has been included in the breakthrough therapy designation program for chronic graft-versus-host disease treatment [10] Group 10 - China Nuclear Technology expects a mid-year profit increase of no less than 15% compared to the previous year [11] Group 11 - Hengrui Medicine's product received orphan drug designation from the FDA, which may provide regulatory advantages in the U.S. market [12] Group 12 - Huaxian Optoelectronics anticipates a significant profit increase of at least 600% for the first half of 2025 [13] Group 13 - New World Development expects a mid-year profit of no less than HKD 800 million, a substantial increase from the previous year's HKD 75.4 million [14] Group 14 - Xinwei Medical expects to achieve a net profit of at least RMB 40 million in the first half of 2025, marking a turnaround from losses [15] Group 15 - Zhiyu Technology anticipates a mid-year profit increase of approximately 108.9% to 126.7% [16] Group 16 - Ningmeng Media expects to achieve a net profit of approximately RMB 10 million to 12 million in the first half of 2025, reversing previous losses [17] Group 17 - Weixin Jinke anticipates a significant profit increase of no less than RMB 200 million for the first half of 2025, reflecting a growth of at least 65% [18] Group 18 - Uni-President China reported a 33.24% increase in shareholder profit to RMB 1.287 billion for the mid-year period [19] Group 19 - BeiGene reported a net profit of USD 94.32 million for the second quarter, marking a turnaround from a loss of USD 120 million in the previous year [20] Group 20 - Maifushi expects to achieve a net profit of approximately RMB 31.8 million to 41 million in the first half of 2025, reversing a significant loss from the previous year [21]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to improved profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains from financial assets measured at fair value through profit or loss [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of newly launched hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to the company's profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains on financial assets measured at fair value through profit or loss [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 承董事會命 上海心瑋醫療科技股份有限公司 正面盈利預告 補充公告 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）刊發。 茲提述本公司日期為2025年7月29日的公告，內容有關（其中包括）本集團截至 2025年6月30日止六個月的正面盈利預告（「該公告」）。除非另行界定，否則本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此補充並知會股東及潛在投資者， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 2025年第二次臨時股東大會通告 茲通告上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 謹訂於2025年8月29日（星期五）上午十時正假座中國上海市自由貿易試驗區臨港新片區 正博路356號8幢4層思脉德廳舉行2025年第二次臨時股東大會（「臨時股東大會」），藉以 審議及酌情通過以下決議案。除另有界定者外，本通告所用詞彙與本公司日期為2025 年8月1日的通函（「通函」）所界定者具有相同涵義。 普通決議案 1. 審議及批准根據組織章程細則、相關法律及法規，利用本公司資本儲備抵銷本公 司虧損人民幣575,0 ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 閣下如對本通函任何方面或將採取的行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交 易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有上海心瑋醫療科技股份有限公司股份，應立即將本通函交予買主或承 讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 本通函僅作參考用途，並不構成收購、購買或認購任何本公司證券的邀請或要約。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） (1) 利用資本儲備抵銷虧損； 及 (2) 2025年第二次臨時股東大會通告 本封面頁所用詞彙與本通函所界定者具相同涵義。 董事會函件載於 ...

Core Viewpoint - The company, Heartway Medical-B (06609.HK), expects to report a significant turnaround in its financial performance, projecting a net profit attributable to shareholders of no less than RMB 40 million for the six months ending June 30, 2025, compared to a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] Financial Performance - The anticipated profit and improvement in performance are primarily attributed to business growth, which has led to an increase in revenue compared to the corresponding period [1] - The overall expense ratio of the company is expected to decline, contributing to the positive financial outlook [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6609） 正面盈利預告 及建議利用資本儲備抵銷虧損 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）刊發。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 董事長 王國輝 正面盈利預告 本公司董事會（「董事會」）欣然通知本公司股東（「股東」）及潛在投資者，根據 對本集團截至2025年6月30日止六個月（「報告期間」）之未經審核綜合管理賬目 之初步評估及董事會現時可得資料，本集團預期錄得股東應佔 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 (I)僱員代表監事變動； 及 (II)委任監事委員會主席 僱員代表監事變動 上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 於2025年7月25日舉行僱員代表會議，並選舉劉紅寶先生（「劉先生」）為本公司 第二屆監事委員會（「監事委員會」）之僱員代表監事（「僱員代表監事」）。委任 劉先生為僱員代表監事將由2025年7月25日起生效，其任期將與第二屆監事委 員會的任期一致，彼於任期內不得就擔任僱員代表監事收取任何薪酬。 於同日，劉柏巍先生因個人工作安排而辭任本公司監事，並不再履行僱員代 表監事及監事委員會主席職務，彼已確認，彼與本公司董事（「董事」）會（「董事 會」）、監事委員會或本公司概無意見分歧，亦無有關其辭任之其他事宜須敦請 本公司股東（「股東」）或香港聯合交易所有限公司（「聯交所」）垂注，亦無彼針 對本集團的現有或待決訴訟或申索。本公司謹藉此機會感謝劉柏巍先生於擔 任本公司 ...

Summary of the Conference Call for Xinwei Medical Industry and Company Overview - The conference call discusses Xinwei Medical's focus on **interventional brain-machine interfaces (BMIs)**, leveraging its existing technology in the **neurovascular field**. The company aims to address complex issues such as paralysis through advanced medical devices [2][5]. Key Points and Arguments 1. **Product Development Timeline**: - Xinwei Medical plans to complete product optimization by **2025**, conduct preclinical tests and animal experiments in **2026**, and initiate non-blind clinical trials by the end of **2026** to early **2027**. The entire process to finalize reports is expected to take **two to three years** [2][10]. 2. **Market Potential**: - Approximately **1.5 to 2 million** new stroke patients are reported annually in China, with a cumulative patient population exceeding **30 million**. This presents a significant demand for rehabilitation solutions [4][18]. 3. **Technical Advantages**: - The interventional approach offers a signal acquisition strength comparable to semi-invasive methods while maintaining lower infection risks and higher safety [3][5]. The existing technology from Xinwei Medical's thrombectomy stents facilitates easier entry into this market [5]. 4. **Clinical Trial Costs**: - The estimated cost for clinical trials is around **200,000 to 300,000 RMB** per patient, with a minimum of **100 patients** required for trials [12][13]. 5. **Regulatory and Reimbursement Landscape**: - Currently, there are no clear regulations for interventional BMIs in the national medical insurance directory. However, future alignment with interventional methods is anticipated as technology matures [14]. 6. **Commercialization Strategy**: - The product will be marketed through hospitals, requiring inclusion in reimbursement directories. The pricing strategy will consider production costs and potential reimbursement to alleviate patient financial burdens [15][19]. 7. **Competitive Landscape**: - Domestic competitors include **Zhonghua Brain Machine**, while international players like **Zenko** have initiated small-scale clinical studies. However, most companies are still in early development stages [2][7]. 8. **Technical Barriers**: - Significant challenges exist in hardware design, particularly for the electrode stent and subcutaneous signal transmission systems. Xinwei Medical's experience over the past nine years provides a competitive edge in overcoming these barriers [8][9]. 9. **Future Adaptations**: - The initial focus is on stroke patients, but there is potential for expanding indications based on technological advancements and market needs [16][17]. 10. **Surgical Considerations**: - The surgical procedure is complex, positioned between interventional and surgical methods, with neurosurgery being the most suitable field for these operations [21]. Additional Important Insights - The current prototype has a high domestic production rate, with core components being locally sourced, indicating a robust domestic supply chain [11]. - The industry is still in its nascent stages, with significant time required for product validation and market introduction, potentially taking **3 to 5 years** for mature products to emerge [25][26]. - The impact of national medical insurance policies on neuro-interventional products is evolving, with a focus on maintaining competitive pricing while ensuring quality care [27].